SCHEMBL6154872

SCHEMBL6154872

COC(=O)c1ccc(NC2CCN(Cc3ccccc3)CC2)c(C)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 3/20 0.54
HSD17B10 Q99714 2/20 0.54
MCHR1 Q99705 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
POLB P06746 1/20 0.52
SIGMAR1 Q99720 2/20 0.52
CHRM4 P08173 1/20 0.52
GAA P10253 2/20 0.51
TSHR P16473 1/20 0.51
OPRM1 P35372 1/20 0.50
OPRD1 P41143 1/20 0.50
OPRK1 P41145 1/20 0.50
DRD4 P21917 1/20 0.50
SLC6A12 P48065 1/20 0.50
SLC6A13 Q9NSD5 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154032 0.90 SLC6A12 (0.56) MEN1KMT2AKDM4EMCHR1SMN1; SMN2
SCHEMBL5118863 0.89 KDM4E (0.54) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL6154012 0.88 OPRK1 (0.55) MEN1KMT2AKDM4EMCHR1SMN1; SMN2
SCHEMBL3491711 0.86 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL8070227 0.83 ALDH1A1 (0.68) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL3493730 0.83 MAPK1 (0.67) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL4225304 0.82 MCHR1 (0.54) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL6153323 0.81 SIGMAR1 (0.60) ALDH1A1KDM4EHSD17B10MCHR1SIGMAR1
SCHEMBL28164487 0.81 SMN1; SMN2 (0.53) ALDH1A1KDM4EHSD17B10SMN1; SMN2GAA
SCHEMBL6153565 0.80 SIGMAR1 (0.59) ALDH1A1KDM4EHSD17B10MCHR1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 MEN1 1993/4885KMT2A 1307/4885ALDH1A1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.